| scholarly article | Q13442814 |
| P2093 | author name string | Ju Guo | |
| Kanghua Li | |||
| Qingsheng Chen | |||
| Jieping Hu | |||
| Runfu Cao | |||
| P2860 | cites work | Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study | Q24596926 |
| Primary Urinary Bladder Angiosarcoma with Osteoclast-Like Multinucleated Giant Cells: A Case Report and Literature Review | Q28078622 | ||
| Androgen receptor in prostate cancer | Q29616454 | ||
| Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor | Q34165500 | ||
| Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells | Q34166215 | ||
| miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells | Q34189798 | ||
| miR 488* inhibits androgen receptor expression in prostate carcinoma cells | Q34196086 | ||
| Androgen receptors in prostate cancer | Q34866937 | ||
| MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells | Q35668910 | ||
| ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. | Q35763908 | ||
| Intravesical treatments of bladder cancer: review. | Q36738254 | ||
| Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth | Q36876865 | ||
| Current state of screening for bladder cancer | Q36879150 | ||
| Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. | Q37000514 | ||
| Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling | Q37148218 | ||
| miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer | Q37375623 | ||
| Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target | Q37606741 | ||
| Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005 | Q37786352 | ||
| Inhibition of T24 and RT4 Human Bladder Cancer Cell Lines by Heterocyclic Molecules | Q38713622 | ||
| N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling. | Q38846470 | ||
| miR-449a targets HDAC-1 and induces growth arrest in prostate cancer | Q39878284 | ||
| Giant Intradiverticular Bladder Tumor | Q40067313 | ||
| Synthesis and antibacterial activities of 5-hydroxy-4-amino-2(5H)-furanones | Q45248216 | ||
| The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study | Q46741922 | ||
| Cell cycle and cancer | Q78834140 | ||
| NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C | Q82939853 | ||
| Total synthesis of (-)-atrop-abyssomicin C | Q83976313 | ||
| P921 | main subject | glucosamine | Q32907954 |
| P304 | page(s) | 2294-2301 | |
| P577 | publication date | 2018-04-16 | |
| P1433 | published in | Medical Science Monitor | Q15756323 |
| P1476 | title | Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration | |
| P478 | volume | 24 |
Search more.